Introduzione
Questa pagina fornisce un'analisi completa dello storico delle operazioni di insider trading note di BVF Partners OS Ltd.. Gli insider sono funzionari, direttori o investitori importanti di una società. In generale, è illegale per gli insider effettuare operazioni di compravendita nelle loro aziende sulla base di informazioni materiali non pubbliche. Ciò non significa che sia illegale per loro effettuare qualsiasi operazioni di trading nelle proprie aziende. Tuttavia, devono segnalare tutte le operazioni alla SEC tramite un modulo 4. Nonostante queste restrizioni, la ricerca accademica suggerisce che gli insider, in generale, tendono a sovraperformare il mercato nelle proprie società.
Redditività media delle transazioni
La redditività media delle transazioni è il rendimento medio di tutti gli acquisti effettuati sul mercato aperto dagli insider negli ultimi tre anni. Pe calcolarla, esaminiamo tutti gli acquisti non pianificati effettuati dall'insider sul mercato aperto, escludendo tutte le operazioni che sono state parte di un piano di trading 10b5-1. Calcoliamo quindi la performance media di queste operazioni nell'arco di 3, 6 e 12 mesi e facciamo la media di ciascuna di queste durate per generare un indicatore di performance finale per ogni operazione. Infine, facciamo la media di tutti gli indicatori di performance per calcolare un indicatore di performance per l'insider. Questo elenco comprende solo gli insider che hanno effettuato almeno tre operazioni negli ultimi due anni.
Se la redditività delle operazioni di questo insider è "N/D", l'insider non ha effettuato acquisti sul mercato aperto negli ultimi tre anni, oppure le operazioni effettuate sono troppo recenti per poter calcolare un indicatore di performance affidabile.
Frequenza di aggiornamento: giornaliera
Società con posizioni di insider dichiarate
I depositi SEC indicano che BVF Partners OS Ltd. ha dichiarato partecipazioni o transazioni nelle seguenti società:
Come interpretare i grafici
I grafici seguenti mostrano l'andamento dei titoli dopo ogni operazione di mercato aperto non pianificata effettuata da BVF Partners OS Ltd.. Per operazioni non pianificate si intendono operazioni non effettuate nell'ambito di un piano di trading 10b5-1. La performance dei titoli è rappresentata come variazione percentuale cumulativa del prezzo delle azioni. Ad esempio, se un'operazione di insider è stata effettuata il 1° gennaio 2019, il grafico mostrerà la variazione percentuale giornaliera del titolo fino ad oggi. Se il prezzo dell'azione passasse da 10 a 15 dollari durante questo periodo, la variazione percentuale cumulativa del prezzo dell'azione sarebbe del 50%. Una variazione di prezzo da 10 a 20 dollari sarebbe del 100%, mentre una variazione di prezzo da 10 a 5 dollari sarebbe del -50%.
In definitiva, cerchiamo di determinare la correlazione tra le operazioni dell'insider e i rendimenti in eccesso (positivi o negativi) del prezzo dell'azione, al fine di capire se l'insider sta programmando le proprie operazioni per trarre profitto da informazioni privilegiate. Immaginiamo che un insider stia facendo questo. In questa situazione, ci aspetteremmo (a) rendimenti positivi dopo gli acquisti, oppure (b) rendimenti negativi dopo le vendite. Nel caso (a), il grafico ACQUISTO mostrerebbe una serie di curve ascendenti, indicando rendimenti positivi dopo ogni operazione di acquisto. Nel caso (b), il grafico VENDITA mostrerebbe una serie di curve inclinate verso il basso, indicando rendimenti negativi dopo ogni operazione di vendita.
Tuttavia, questo non è sufficiente per trarre conclusioni. Se, ad esempio, il prezzo delle azioni della società è aumentato in maniera non ciclica per molti anni, allora ci aspetteremmo che tutti i grafici post-acquisto abbiano una pendenza rivolta verso l'alto. Allo stesso modo, ribassi non ciclici per molti anni darebbero luogo a grafici post-negoziazione rivolti verso il basso. Nessuno di questi grafici suggerisce un'attività di insider trading.
L'indicatore più forte sarebbe una situazione in cui il prezzo delle azioni fosse estremamente ciclico e vi fossero segnali positivi nel grafico ACQUISTO e curve negative nel grafico VENDITA. Questa situazione suggerirebbe che l'insider sta programmando le operazioni di trading per trarne un vantaggio finanziario.
Acquisti di insider CALA / Calithera Biosciences, Inc. - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider CALA / Calithera Biosciences, Inc. - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider CGEM / Cullinan Therapeutics, Inc. - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider CGEM / Cullinan Therapeutics, Inc. - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al minimo |
Prezzo al minimo |
Perdita massima evitata ($) |
Perdita massima evitata (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider CTMX / CytomX Therapeutics, Inc. - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al massimo |
Prezzo al massimo |
Profitto massimo ($) |
Rendimento massimo (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider CTMX / CytomX Therapeutics, Inc. - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al minimo |
Prezzo al minimo |
Perdita massima evitata ($) |
Perdita massima evitata (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider CYTK / Cytokinetics, Incorporated - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider CYTK / Cytokinetics, Incorporated - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider ELDN / Eledon Pharmaceuticals, Inc. - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider ELDN / Eledon Pharmaceuticals, Inc. - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al minimo |
Prezzo al minimo |
Perdita massima evitata ($) |
Perdita massima evitata (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider FDMT / 4D Molecular Therapeutics, Inc. - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al massimo |
Prezzo al massimo |
Profitto massimo ($) |
Rendimento massimo (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider FDMT / 4D Molecular Therapeutics, Inc. - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al minimo |
Prezzo al minimo |
Perdita massima evitata ($) |
Perdita massima evitata (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al massimo |
Prezzo al massimo |
Profitto massimo ($) |
Rendimento massimo (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al minimo |
Prezzo al minimo |
Perdita massima evitata ($) |
Perdita massima evitata (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider IDYA / IDEAYA Biosciences, Inc. - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider IDYA / IDEAYA Biosciences, Inc. - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider IMUX / Immunic, Inc. - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al massimo |
Prezzo al massimo |
Profitto massimo ($) |
Rendimento massimo (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider IMUX / Immunic, Inc. - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al minimo |
Prezzo al minimo |
Perdita massima evitata ($) |
Perdita massima evitata (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider INFIQ / Infinity Pharmaceuticals, Inc. - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider INFIQ / Infinity Pharmaceuticals, Inc. - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider KYMR / Kymera Therapeutics, Inc. - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider KYMR / Kymera Therapeutics, Inc. - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al minimo |
Prezzo al minimo |
Perdita massima evitata ($) |
Perdita massima evitata (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider MLTX / MoonLake Immunotherapeutics - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al massimo |
Prezzo al massimo |
Profitto massimo ($) |
Rendimento massimo (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider MLTX / MoonLake Immunotherapeutics - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider OLMA / Olema Pharmaceuticals, Inc. - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider OLMA / Olema Pharmaceuticals, Inc. - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al minimo |
Prezzo al minimo |
Perdita massima evitata ($) |
Perdita massima evitata (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider SNDX / Syndax Pharmaceuticals, Inc. - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al massimo |
Prezzo al massimo |
Profitto massimo ($) |
Rendimento massimo (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider SNDX / Syndax Pharmaceuticals, Inc. - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al minimo |
Prezzo al minimo |
Perdita massima evitata ($) |
Perdita massima evitata (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider VSTM / Verastem, Inc. - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al massimo |
Prezzo al massimo |
Profitto massimo ($) |
Rendimento massimo (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider VSTM / Verastem, Inc. - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al minimo |
Prezzo al minimo |
Perdita massima evitata ($) |
Perdita massima evitata (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider XENE / Xenon Pharmaceuticals Inc. - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider XENE / Xenon Pharmaceuticals Inc. - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
| Data dell'operazione | Ticker | Insider | Azioni dichiarate |
Prezzo dichiarato |
Azioni rettificate |
Prezzo rettificato |
Base di costo | Giorni fino al minimo |
Prezzo al minimo |
Perdita massima evitata ($) |
Perdita massima evitata (%) |
|---|---|---|---|---|---|---|---|
| Non sono note operazioni di mercato aperto non pianificate per questa combinazione di insider e titoli. |
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Acquisti di insider XOMAO / XOMA Royalty Corporation - Preferred Stock - Analisi degli utili a breve termine
In questa sezione analizziamo la redditività di ogni acquisto non pianificato di insider sul mercato aperto effettuato in CALA / Calithera Biosciences, Inc.. Questa analisi aiuta a capire se l'insider genera costantemente rendimenti anomali e se vale la pena seguirlo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra gli acquisti più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Vendite di insider XOMAO / XOMA Royalty Corporation - Preferred Stock - Analisi delle perdite a breve termine
In questa sezione, analizziamo l'evitamento delle perdite a breve termine di ogni vendita di insider non pianificata ed effettuata sul mercato aperto in CALA / Calithera Biosciences, Inc.. Un modello coerente di evitamento delle perdite può suggerire che future transazioni di vendita potrebbero predire cali di prezzo. L'analisi riguarda l'anno successivo a ciascuna operazione, e i risultati sono teorici.
La tabella seguente mostra le vendite più recenti sul mercato aperto che non facevano parte di un piano di trading automatico.
Il prezzo rettificato è il prezzo rettificato per il frazionamento azionario. Leazioni rettificate sono le azioni rettificate per il frazionamento azionario.
Storico delle operazioni degli insider
Questa tabella mostra l'elenco completo delle operazioni effettuate da BVF Partners OS Ltd. come comunicato alla Securities Exchange Commission (SEC).
| Data di deposito | Data della transazione | Modulo | Ticker | Titolo | Codice | Azioni | Azioni rimanenti | Variazione percentuale |
Prezzo dell'azione |
Valore della transazione |
Valore rimanente |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 772.000 | 772.000 | 4,03 | 3.111.160 | 3.111.160 | ||
| 2026-05-18 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 412.000 | 412.000 | 4,03 | 1.660.360 | 1.660.360 | ||
| 2026-05-18 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 1.506.000 | 2.773.545 | 118,81 | 4,03 | 6.069.180 | 11.177.386 | |
| 2026-05-18 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 2.313.000 | 3.635.758 | 174,86 | 4,03 | 9.321.390 | 14.652.105 | |
| 2026-04-02 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -248.530 | 1.039.238 | -19,30 | 16,79 | -4.172.819 | 17.448.806 | |
| 2026-04-02 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -1.569.116 | 6.599.722 | -19,21 | 16,79 | -26.345.458 | 110.809.332 | |
| 2026-04-02 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -1.932.354 | 8.302.735 | -18,88 | 16,79 | -32.444.224 | 139.402.921 | |
| 2026-02-27 | 3 | IMUX |
IMMUNIC, INC.
Common Stock, $0.0001 par value |
4.135.956 | ||||||||
| 2026-02-27 | 3 | IMUX |
IMMUNIC, INC.
Common Stock, $0.0001 par value |
3.027.105 | ||||||||
| 2026-02-27 | 3 | IMUX |
IMMUNIC, INC.
Common Stock, $0.0001 par value |
427.629 | ||||||||
| 2026-01-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
U - Other | -548.938 | 0 | -100,00 | ||||
| 2026-01-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
U - Other | -4.308.573 | 0 | -100,00 | ||||
| 2026-01-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
U - Other | -5.309.432 | 0 | -100,00 | ||||
| 2025-10-14 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
U - Other | -560.797 | 0 | -100,00 | ||||
| 2025-10-14 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
U - Other | -4.726.743 | 0 | -100,00 | ||||
| 2025-10-14 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
U - Other | -6.194.145 | 0 | -100,00 | ||||
| 2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -11 | 560.797 | 0,00 | 1,88 | -21 | 1.053.121 | |
| 2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -66 | 4.726.743 | 0,00 | 1,88 | -124 | 8.876.351 | |
| 2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -79 | 6.194.145 | 0,00 | 1,88 | -148 | 11.631.985 | |
| 2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 203.336 | 560.808 | 56,88 | 0,00 | 20 | 56 | |
| 2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 1.235.030 | 4.726.809 | 35,37 | 0,00 | 124 | 473 | |
| 2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 1.481.634 | 6.194.224 | 31,44 | 0,00 | 148 | 619 | |
| 2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 58.780 | 353.412 | 19,95 | 44,00 | 2.586.320 | 15.550.128 | |
| 2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 115.783 | 2.219.858 | 5,50 | 44,00 | 5.094.452 | 97.673.752 | |
| 2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 142.604 | 2.798.795 | 5,37 | 44,00 | 6.274.576 | 123.146.980 | |
| 2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 56.079 | 62.383 | 889,58 | ||||
| 2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 556.617 | 593.740 | 1.499,39 | ||||
| 2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 657.308 | 707.116 | 1.319,68 | ||||
| 2025-05-20 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -265.316 | 1.267.545 | -17,31 | 27,10 | -7.190.064 | 34.350.470 | |
| 2025-05-20 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -127.407 | 1.322.758 | -8,79 | 27,10 | -3.452.730 | 35.846.742 | |
| 2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -855.211 | 0 | -100,00 | ||||
| 2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -6.777.935 | 0 | -100,00 | ||||
| 2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -8.679.726 | 0 | -100,00 | ||||
| 2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -149.975 | 0 | -100,00 | 26,10 | -3.914.348 | ||
| 2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -75.287 | 0 | -100,00 | 26,10 | -1.964.991 | ||
| 2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -85.776 | 1.532.861 | -5,30 | 26,10 | -2.238.754 | 40.007.672 | |
| 2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -339.679 | 1.450.165 | -18,98 | 26,10 | -8.865.622 | 37.849.306 | |
| 2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -22.740 | 347.970 | -6,13 | ||||
| 2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -161.810 | 2.003.966 | -7,47 | ||||
| 2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -235.450 | 2.655.977 | -8,14 | ||||
| 2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 29.648 | 38.961 | 318,35 | ||||
| 2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 174.958 | 282.223 | 163,11 | ||||
| 2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 234.323 | 371.916 | 170,30 | ||||
| 2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -153.441 | 370.710 | -29,27 | ||||
| 2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -1.418.736 | 2.165.776 | -39,58 | ||||
| 2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -1.797.527 | 2.891.427 | -38,34 | ||||
| 2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -240.000 | 87.911 | -73,19 | ||||
| 2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -2.378.000 | 662.970 | -78,20 | ||||
| 2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -3.062.000 | 830.237 | -78,67 | ||||
| 2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -64.617 | 176.692 | -26,78 | 14,30 | -924.023 | 2.526.696 | |
| 2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -396.963 | 1.367.257 | -22,50 | 14,30 | -5.676.571 | 19.551.775 | |
| 2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -538.420 | 1.794.218 | -23,08 | 14,30 | -7.699.406 | 25.657.317 | |
| 2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -132.549 | 1.287.768 | -9,33 | 50,00 | -6.627.662 | 64.390.460 | |
| 2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -836.862 | 8.168.838 | -9,29 | 50,00 | -41.844.439 | 408.454.970 | |
| 2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -1.030.589 | 10.235.089 | -9,15 | 50,00 | -51.531.099 | 511.770.826 | |
| 2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
3.892.237 | ||||||||
| 2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
3.040.970 | ||||||||
| 2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
327.911 | ||||||||
| 2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 75.431 | 220.460 | 52,01 | ||||
| 2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 821.121 | 2.633.679 | 45,30 | ||||
| 2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.031.385 | 3.361.803 | 44,26 | ||||
| 2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -341.547 | 0 | -100,00 | ||||
| 2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -185.388 | 0 | -100,00 | ||||
| 2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -2.076.085 | 0 | -100,00 | ||||
| 2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -1.367.838 | 0 | -100,00 | ||||
| 2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -2.870.985 | 0 | -100,00 | ||||
| 2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -1.734.960 | 0 | -100,00 | ||||
| 2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
8.679.726 | ||||||||
| 2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
6.777.935 | ||||||||
| 2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
855.211 | ||||||||
| 2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -896.366 | 0 | -100,00 | 12,45 | -11.159.757 | ||
| 2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -7.290.667 | 0 | -100,00 | 12,45 | -90.768.804 | ||
| 2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -8.974.245 | 0 | -100,00 | 12,45 | -111.729.350 | ||
| 2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 16.143 | 548.938 | 3,03 | 5,38 | 86.909 | 2.955.318 | |
| 2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 125.909 | 4.308.573 | 3,01 | 5,38 | 677.856 | 23.196.064 | |
| 2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 153.693 | 5.309.432 | 2,98 | 5,38 | 827.437 | 28.584.389 | |
| 2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 47.712 | 532.795 | 9,84 | 5,00 | 238.555 | 2.663.922 | |
| 2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 390.507 | 4.182.664 | 10,30 | 5,00 | 1.952.496 | 20.912.902 | |
| 2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 493.337 | 5.155.739 | 10,58 | 5,00 | 2.466.636 | 25.778.179 | |
| 2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
1.204.412 | ||||||||
| 2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
912.776 | ||||||||
| 2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
104.257 | ||||||||
| 2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
8.974.245 | ||||||||
| 2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
7.290.667 | ||||||||
| 2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
896.366 | ||||||||
| 2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10.106 | 294.632 | 3,55 | 14,07 | 142.180 | 4.145.148 | |
| 2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 83.708 | 2.104.075 | 4,14 | 14,07 | 1.177.679 | 29.602.021 | |
| 2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 103.885 | 2.656.191 | 4,07 | 14,07 | 1.461.548 | 37.369.686 | |
| 2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 26.772 | 284.526 | 10,39 | 11,64 | 311.744 | 3.313.135 | |
| 2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 132.016 | 2.020.367 | 6,99 | 11,64 | 1.537.247 | 23.525.961 | |
| 2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 57.618 | 2.552.306 | 2,31 | 11,64 | 670.927 | 29.720.072 | |
| 2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 72.479 | 485.083 | 17,57 | 3,60 | 260.924 | 1.746.299 | |
| 2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 492.251 | 3.792.157 | 14,92 | 3,60 | 1.772.104 | 13.651.765 | |
| 2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 218.979 | 4.662.402 | 4,93 | 3,60 | 788.324 | 16.784.647 | |
| 2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
J - Other | 99.556 | 99.556 | |||||
| 2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 52.801 | 524.151 | 11,20 | 9,84 | 519.562 | 5.157.646 | |
| 2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 677.853 | 3.584.512 | 23,32 | 9,84 | 6.670.074 | 35.271.598 | |
| 2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 775.278 | 4.688.954 | 19,81 | 9,84 | 7.628.736 | 46.139.307 | |
| 2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -43.139 | 0 | -100,00 | 9,10 | -392.565 | ||
| 2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -1.526.147 | 0 | -100,00 | 9,10 | -13.887.938 | ||
| 2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -702.505 | 0 | -100,00 | 9,10 | -6.392.796 | ||
| 2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -2.595.239 | 0 | -100,00 | 9,10 | -23.616.675 | ||
| 2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -3.989.130 | 0 | -100,00 | 9,10 | -36.301.083 | ||
| 2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
11.007.420 | ||||||||
| 2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
8.581.171 | ||||||||
| 2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
744.966 | ||||||||
| 2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -462.605 | 0 | -100,00 | ||||
| 2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -2.929.660 | 0 | -100,00 | ||||
| 2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -4.018.253 | 0 | -100,00 | ||||
| 2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 86.341 | 145.029 | 147,12 | ||||
| 2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 837.146 | 1.812.558 | 85,82 | ||||
| 2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.055.445 | 2.330.418 | 82,78 | ||||
| 2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
4.018.253 | ||||||||
| 2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2.801.529 | ||||||||
| 2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2.929.660 | ||||||||
| 2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2.130.657 | ||||||||
| 2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
462.605 | ||||||||
| 2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
241.755 | ||||||||
| 2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -300.000 | 64.161 | -82,38 | ||||
| 2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -2.600.000 | 392.808 | -86,87 | ||||
| 2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -3.500.000 | 558.854 | -86,23 | ||||
| 2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 15.912 | 1.888.351 | 0,85 | 31,24 | 497.132 | 58.996.995 | |
| 2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 2.985 | 2.494.688 | 0,12 | 31,24 | 93.259 | 77.940.539 | |
| 2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 11.149 | 1.872.439 | 0,60 | 29,89 | 333.209 | 55.961.397 | |
| 2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10.961 | 2.491.703 | 0,44 | 29,89 | 327.590 | 74.469.278 | |
| 2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.573 | 1.618.637 | 0,10 | 21,98 | 34.577 | 35.580.393 | |
| 2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.676 | 1.789.844 | 0,09 | 21,98 | 36.841 | 39.343.814 | |
| 2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 15.670 | 1.617.064 | 0,98 | 18,39 | 288.096 | 29.730.045 | |
| 2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.330 | 1.788.168 | 0,19 | 18,39 | 61.223 | 32.875.826 | |
| 2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 9.597 | 241.309 | 4,14 | 4,11 | 39.430 | 991.442 | |
| 2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 87.831 | 1.764.220 | 5,24 | 4,11 | 360.862 | 7.248.474 | |
| 2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 116.635 | 2.332.638 | 5,26 | 4,11 | 479.207 | 9.583.876 | |
| 2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
2.216.003 | ||||||||
| 2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
1.676.389 | ||||||||
| 2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
231.712 | ||||||||
| 2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 54.857 | 341.547 | 19,13 | 5,83 | 319.816 | 1.991.219 | |
| 2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 685.330 | 2.076.085 | 49,28 | 5,83 | 3.995.474 | 12.103.576 | |
| 2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 970.171 | 2.870.985 | 51,04 | 5,83 | 5.656.097 | 16.737.843 | |
| 2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 678 | 1.601.394 | 0,04 | 16,89 | 11.452 | 27.047.865 | |
| 2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.004 | 1.784.838 | 0,06 | 16,89 | 16.958 | 30.146.271 | |
| 2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.021 | 1.600.716 | 0,19 | 16,83 | 50.849 | 26.942.771 | |
| 2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.339 | 1.783.834 | 0,19 | 16,83 | 56.201 | 30.024.959 | |
| 2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.885 | 1.597.695 | 0,62 | 16,50 | 163.073 | 26.357.174 | |
| 2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6.715 | 1.780.495 | 0,38 | 16,50 | 110.777 | 29.372.826 | |
| 2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 13.396 | 1.773.780 | 0,76 | 17,89 | 239.618 | 31.728.135 | |
| 2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.897 | 1.587.810 | 0,69 | 17,89 | 194.918 | 28.401.634 | |
| 2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 5.575 | 1.576.913 | 0,35 | 17,96 | 100.138 | 28.324.511 | |
| 2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 26.441 | 1.571.338 | 1,71 | 17,25 | 456.044 | 27.101.809 | |
| 2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 27.117 | 257.754 | 11,76 | 26,00 | 705.042 | 6.701.604 | |
| 2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 233.362 | 1.861.290 | 14,33 | 26,00 | 6.067.412 | 48.393.540 | |
| 2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 285.046 | 2.480.742 | 12,98 | 26,00 | 7.411.196 | 64.499.292 | |
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 1.519.999 | 1.526.147 | 24.723,47 | ||||
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -1.289.434 | 6.148 | -99,53 | 6,12 | -7.891.336 | 37.626 | |
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 682.666 | 702.505 | 3.441,03 | ||||
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -469.040 | 19.839 | -95,94 | 6,12 | -2.870.525 | 121.415 | |
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 2.426.666 | 2.595.239 | 1.439,53 | ||||
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -2.890.723 | 168.573 | -94,49 | 6,12 | -17.691.225 | 1.031.667 | |
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 3.754.000 | 3.989.130 | 1.596,56 | ||||
| 2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -3.850.803 | 235.130 | -94,25 | 6,12 | -23.566.914 | 1.438.996 | |
| 2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
4.712.590 | ||||||||
| 2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
3.491.779 | ||||||||
| 2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
357.472 | ||||||||
| 2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
2.132.411 | ||||||||
| 2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
1.570.857 | ||||||||
| 2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
209.716 | ||||||||
| 2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 6.168 | 412.604 | 1,52 | 12,73 | 78.519 | 5.252.449 | |
| 2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 68.327 | 3.299.906 | 2,11 | 12,73 | 869.803 | 42.007.803 | |
| 2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 74.666 | 4.443.423 | 1,71 | 12,73 | 950.498 | 56.564.775 | |
| 2022-06-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 41.417 | 2.906.659 | 1,45 | 4,03 | 167.097 | 11.726.916 | |
| 2022-06-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 158.583 | 3.913.676 | 4,22 | 4,03 | 639.803 | 15.789.726 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 20 | 406.436 | 0,00 | 13,21 | 264 | 5.369.751 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 3.040 | 3.231.579 | 0,09 | 13,21 | 40.164 | 42.694.975 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 3.809 | 4.368.757 | 0,09 | 13,21 | 50.324 | 57.719.144 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 31.903 | 406.416 | 8,52 | 12,29 | 391.960 | 4.993.227 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 258.797 | 3.228.539 | 8,71 | 12,29 | 3.179.580 | 39.665.830 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 353.344 | 4.364.948 | 8,81 | 12,29 | 4.341.184 | 53.627.751 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 61.156 | 374.513 | 19,52 | 11,68 | 714.449 | 4.375.211 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 464.235 | 2.969.742 | 18,53 | 11,68 | 5.423.379 | 34.693.714 | |
| 2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 660.654 | 4.011.604 | 19,72 | 11,68 | 7.718.024 | 46.865.163 | |
| 2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 44.746 | 364.161 | 14,01 | 11,00 | 492.179 | 4.005.553 | |
| 2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 301.009 | 2.992.808 | 11,18 | 11,00 | 3.310.918 | 32.919.092 | |
| 2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 405.641 | 4.058.854 | 11,10 | 11,00 | 4.461.808 | 44.644.959 | |
| 2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 3.223 | 230.637 | 1,42 | 14,78 | 47.645 | 3.409.461 | |
| 2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 26.353 | 1.627.928 | 1,65 | 14,78 | 389.571 | 24.065.334 | |
| 2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 35.793 | 2.195.696 | 1,66 | 14,78 | 529.121 | 32.458.535 | |
| 2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10.642 | 227.414 | 4,91 | 14,21 | 151.229 | 3.231.689 | |
| 2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 90.372 | 1.601.575 | 5,98 | 14,21 | 1.284.240 | 22.759.342 | |
| 2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 123.043 | 2.159.903 | 6,04 | 14,21 | 1.748.515 | 30.693.518 | |
| 2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 37 | 216.772 | 0,02 | 14,00 | 518 | 3.034.678 | |
| 2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4.180 | 1.511.203 | 0,28 | 14,00 | 58.517 | 21.155.935 | |
| 2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 5.883 | 2.036.860 | 0,29 | 14,00 | 82.358 | 28.514.818 | |
| 2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 5.730 | 313.357 | 1,86 | 8,50 | 48.705 | 2.663.534 | |
| 2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 189.882 | 2.505.507 | 8,20 | 8,50 | 1.613.997 | 21.296.810 | |
| 2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 224.388 | 3.350.950 | 7,18 | 8,50 | 1.907.298 | 28.483.075 | |
| 2022-05-20 |
|
4 | XOMA |
XOMA Corp
Non-Qualified Stock Option (right to buy) |
A - Award | 8.996 | 8.996 | |||||
| 2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 17.744 | 319.415 | 5,88 | 9,14 | 162.091 | 2.917.856 | |
| 2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 38.558 | 2.691.799 | 1,45 | 9,14 | 352.227 | 24.589.584 | |
| 2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 53.598 | 3.653.213 | 1,49 | 9,14 | 489.618 | 33.372.101 | |
| 2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 457.001 | 2.653.241 | 20,81 | 9,06 | 4.140.429 | 24.038.363 | |
| 2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 542.999 | 3.599.615 | 17,76 | 9,06 | 4.919.571 | 32.612.512 | |
| 2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4.131 | 216.735 | 1,94 | 19,26 | 79.542 | 4.173.232 | |
| 2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 40.659 | 1.507.023 | 2,77 | 19,26 | 782.889 | 29.017.728 | |
| 2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 55.210 | 2.030.977 | 2,79 | 19,26 | 1.063.069 | 39.106.462 | |
| 2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4.066 | 212.604 | 1,95 | 19,60 | 79.690 | 4.166.847 | |
| 2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 70.439 | 1.466.364 | 5,05 | 19,60 | 1.380.541 | 28.739.415 | |
| 2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 75.495 | 1.975.767 | 3,97 | 19,60 | 1.479.634 | 38.723.255 | |
| 2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
11.265.678 | ||||||||
| 2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
9.005.699 | ||||||||
| 2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
1.420.317 | ||||||||
| 2022-04-05 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 9.402 | 2.196.240 | 0,43 | 10,75 | 101.071 | 23.609.360 | |
| 2022-04-05 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 266.598 | 3.056.616 | 9,56 | 10,75 | 2.865.902 | 32.858.316 | |
| 2022-03-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Stock Option (Right to Buy) |
A - Award | 80.000 | 80.000 | |||||
| 2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
10.753.294 | ||||||||
| 2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
7.883.287 | ||||||||
| 2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
994.353 | ||||||||
| 2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 14.323 | 1.395.925 | 1,04 | 40,70 | 582.946 | 56.814.148 | |
| 2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 20.085 | 1.900.272 | 1,07 | 40,70 | 817.460 | 77.341.070 | |
| 2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 37.859 | 1.381.602 | 2,82 | 38,33 | 1.451.207 | 52.959.430 | |
| 2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 58.042 | 1.880.187 | 3,19 | 38,33 | 2.224.860 | 72.071.140 | |
| 2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
1.274.973 | ||||||||
| 2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
975.412 | ||||||||
| 2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
58.688 | ||||||||
| 2022-01-26 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 114.726 | 1.343.743 | 9,33 | 37,76 | 4.332.455 | 50.744.439 | |
| 2022-01-26 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 158.041 | 1.822.145 | 9,50 | 37,76 | 5.968.181 | 68.810.573 | |
| 2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 7.899 | 307.627 | 2,64 | 14,10 | 111.376 | 4.337.541 | |
| 2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 412.264 | 2.315.625 | 21,66 | 14,10 | 5.812.922 | 32.650.312 | |
| 2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 577.798 | 3.126.562 | 22,67 | 14,10 | 8.146.952 | 44.084.524 | |
| 2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
2.790.018 | ||||||||
| 2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
2.186.838 | ||||||||
| 2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
301.671 | ||||||||
| 2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 14.806 | 185.388 | 8,68 | 12,00 | 177.672 | 2.224.656 | |
| 2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 226.079 | 1.367.838 | 19,80 | 12,00 | 2.712.948 | 16.414.056 | |
| 2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 255.500 | 1.734.960 | 17,27 | 12,00 | 3.066.000 | 20.819.520 | |
| 2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 61.343 | 1.141.759 | 5,68 | 12,00 | 736.018 | 13.699.281 | |
| 2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 35.268 | 471.350 | 8,09 | 9,39 | 331.177 | 4.426.118 | |
| 2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 341.977 | 2.865.242 | 13,55 | 9,39 | 3.211.267 | 26.905.482 | |
| 2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 362.430 | 3.755.093 | 10,68 | 9,39 | 3.403.326 | 35.261.450 | |
| 2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
2.548.764 | ||||||||
| 2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
1.903.361 | ||||||||
| 2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
299.728 | ||||||||
| 2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -8.929 | 232.747 | -3,69 | 27,79 | -248.106 | 6.467.225 | |
| 2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -58.327 | 1.520.405 | -3,69 | 27,79 | -1.620.703 | 42.246.734 | |
| 2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -80.011 | 2.085.664 | -3,69 | 27,79 | -2.223.226 | 57.953.303 | |
| 2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -69.534 | 241.676 | -22,34 | 27,53 | -1.914.348 | 6.653.606 | |
| 2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -384.914 | 1.578.732 | -19,60 | 27,53 | -10.597.106 | 43.464.229 | |
| 2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -530.999 | 2.165.675 | -19,69 | 27,53 | -14.618.987 | 59.623.415 | |
| 2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 590 | 170.582 | 0,35 | 13,94 | 8.226 | 2.378.357 | |
| 2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 4.102 | 1.080.416 | 0,38 | 13,94 | 57.193 | 15.063.808 | |
| 2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.341 | 1.479.460 | 0,43 | 13,94 | 88.410 | 20.627.519 | |
| 2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 20.512 | 169.992 | 13,72 | 16,49 | 338.243 | 2.803.168 | |
| 2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 158.511 | 1.076.314 | 17,27 | 16,49 | 2.613.846 | 17.748.418 | |
| 2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 213.246 | 1.473.119 | 16,93 | 16,49 | 3.516.427 | 24.291.732 | |
| 2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -150.805 | 311.210 | -32,64 | 20,75 | -3.129.204 | 6.457.608 | |
| 2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -928.739 | 1.963.646 | -32,11 | 20,75 | -19.271.334 | 40.745.654 | |
| 2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -1.106.478 | 2.696.674 | -29,09 | 20,75 | -22.959.418 | 55.955.986 | |
| 2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 27.458 | 208.538 | 15,16 | 47,00 | 1.290.526 | 9.801.286 | |
| 2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 211.711 | 1.229.017 | 20,81 | 47,00 | 9.950.417 | 57.763.799 | |
| 2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 304.997 | 1.664.104 | 22,44 | 47,00 | 14.334.859 | 78.212.888 | |
| 2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 16.980 | 149.480 | 12,82 | 15,25 | 258.945 | 2.279.570 | |
| 2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 106.627 | 917.803 | 13,14 | 15,25 | 1.626.062 | 13.996.496 | |
| 2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 146.116 | 1.259.873 | 13,12 | 15,25 | 2.228.269 | 19.213.063 | |
| 2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 20.018 | 132.500 | 17,80 | 15,65 | 313.282 | 2.073.625 | |
| 2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 124.804 | 811.176 | 18,18 | 15,65 | 1.953.183 | 12.694.904 | |
| 2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 172.457 | 1.113.757 | 18,32 | 15,65 | 2.698.952 | 17.430.297 | |
| 2021-06-21 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 20.063 | 20.063 | |||||
| 2021-05-26 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
J - Other | 99.556 | 99.556 | |||||
| 2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 129 | 112.482 | 0,11 | 15,90 | 2.050 | 1.787.924 | |
| 2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 513 | 686.372 | 0,07 | 15,90 | 8.154 | 10.910.020 | |
| 2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 719 | 941.300 | 0,08 | 15,90 | 11.429 | 14.962.152 | |
| 2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 7.592 | 112.353 | 7,25 | 15,94 | 121.032 | 1.791.132 | |
| 2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 48.152 | 685.859 | 7,55 | 15,94 | 767.639 | 10.933.964 | |
| 2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 66.242 | 940.581 | 7,58 | 15,94 | 1.056.030 | 14.994.742 | |
| 2021-05-21 |
|
4 | XOMA |
XOMA Corp
Non-Qualified Stock Option (right to buy) |
A - Award | 5.101 | 5.101 | |||||
| 2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.115 | 104.761 | 1,08 | 15,88 | 17.711 | 1.664.055 | |
| 2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.962 | 637.707 | 1,10 | 15,88 | 110.586 | 10.129.529 | |
| 2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 9.191 | 874.339 | 1,06 | 15,88 | 145.993 | 13.888.263 | |
| 2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 11.946 | 103.646 | 13,03 | 16,65 | 198.901 | 1.725.706 | |
| 2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 75.640 | 630.745 | 13,63 | 16,65 | 1.259.406 | 10.501.904 | |
| 2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 103.611 | 865.148 | 13,61 | 16,65 | 1.725.123 | 14.404.714 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.747 | 88.226 | 2,02 | 14,90 | 26.032 | 1.314.647 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 10.876 | 532.384 | 2,09 | 14,90 | 162.062 | 7.933.001 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 14.790 | 729.732 | 2,07 | 14,90 | 220.384 | 10.873.664 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.141 | 86.479 | 7,64 | 15,93 | 97.817 | 1.377.481 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 62.948 | 80.338 | 361,98 | 17,00 | 1.070.116 | 1.365.746 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 38.858 | 521.508 | 8,05 | 15,93 | 618.950 | 8.306.840 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 398.300 | 482.650 | 472,20 | 17,00 | 6.771.100 | 8.205.050 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 53.303 | 714.942 | 8,06 | 15,93 | 849.037 | 11.387.954 | |
| 2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 546.346 | 661.639 | 473,88 | 17,00 | 9.287.882 | 11.247.863 | |
| 2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 3.474 | 91.700 | 3,94 | 14,26 | 49.544 | 1.307.780 | |
| 2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 22.721 | 555.105 | 4,27 | 14,26 | 324.036 | 7.916.630 | |
| 2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 31.805 | 761.537 | 4,36 | 14,26 | 453.587 | 10.860.660 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 1.747 | 88.226 | 2,02 | 14,90 | 26.032 | 1.314.647 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 10.876 | 532.384 | 2,09 | 14,90 | 162.062 | 7.933.001 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 14.790 | 729.732 | 2,07 | 14,90 | 220.384 | 10.873.664 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -134.515 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -152.176 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -17.390 | 152.176 | -10,26 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -837.397 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -553.359 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -84.350 | 553.359 | -13,23 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.068.554 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -832.261 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -115.293 | 832.261 | -12,17 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 134.515 | 286.691 | 88,39 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 152.176 | 152.176 | |||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 6.141 | 86.479 | 7,64 | 15,93 | 97.817 | 1.377.481 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 62.948 | 80.338 | 361,98 | 17,00 | 1.070.116 | 1.365.746 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 17.390 | 17.390 | |||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 837.397 | 1.390.756 | 151,33 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 553.359 | 553.359 | |||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 38.858 | 521.508 | 8,05 | 15,93 | 618.950 | 8.306.840 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 398.300 | 482.650 | 472,20 | 17,00 | 6.771.100 | 8.205.050 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 84.350 | 84.350 | |||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 1.068.554 | 1.900.815 | 128,39 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 832.261 | 832.261 | |||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 53.303 | 714.942 | 8,06 | 15,93 | 849.037 | 11.387.954 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 546.346 | 661.639 | 473,88 | 17,00 | 9.287.882 | 11.247.863 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 115.293 | 115.293 | |||||
| 2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 17 | 17 | 25.000,00 | 425.000 | 425.000 | ||
| 2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 239 | 239 | 25.000,00 | 5.975.000 | 5.975.000 | ||
| 2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 344 | 344 | 25.000,00 | 8.600.000 | 8.600.000 | ||
| 2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 5.171 | 488.879 | 1,07 | 2,50 | 12.928 | 1.222.198 | |
| 2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 950.016 | 3.059.296 | 45,04 | 2,50 | 2.375.040 | 7.648.240 | |
| 2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 1.044.813 | 4.085.933 | 34,36 | 2,50 | 2.612.032 | 10.214.832 | |
| 2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -81.903 | 149.975 | -35,32 | 38,36 | -3.141.799 | 5.753.041 | |
| 2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -84.250 | 75.287 | -52,81 | 38,36 | -3.231.830 | 2.888.009 | |
| 2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -205.807 | 1.544.897 | -11,76 | 38,36 | -7.894.757 | 59.262.249 | |
| 2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -279.740 | 1.760.384 | -13,71 | 38,36 | -10.730.826 | 67.528.330 | |
| 2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 26.894 | 462.015 | 6,18 | 19,75 | 531.156 | 9.124.796 | |
| 2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 108.106 | 2.892.385 | 3,88 | 19,75 | 2.135.094 | 57.124.604 | |
| 2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 165.000 | 3.803.152 | 4,54 | 19,75 | 3.258.750 | 75.112.252 | |
| 2021-03-24 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 7.744 | 435.121 | 1,81 | 22,75 | 176.176 | 9.899.003 | |
| 2021-03-24 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 71.756 | 3.638.152 | 2,01 | 22,75 | 1.632.449 | 82.767.958 | |
| 2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 1.171 | 427.377 | 0,27 | 23,00 | 26.933 | 9.829.500 | |
| 2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 195.768 | 2.784.279 | 7,56 | 23,00 | 4.502.586 | 64.037.303 | |
| 2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 53.061 | 3.566.396 | 1,51 | 23,00 | 1.220.382 | 82.025.681 | |
| 2021-03-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Stock Option (Right to Buy) |
A - Award | 80.000 | 80.000 | |||||
| 2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
3.372.098 | ||||||||
| 2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
2.484.643 | ||||||||
| 2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
405.344 | ||||||||
| 2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -152.127 | 534.847 | -22,14 | 5,37 | -816.709 | 2.871.380 | |
| 2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -892.467 | 3.279.831 | -21,39 | 5,37 | -4.791.298 | 17.608.101 | |
| 2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -1.215.491 | 4.448.421 | -21,46 | 5,37 | -6.525.485 | 23.881.793 | |
| 2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -4.325 | 233.150 | -1,82 | 18,00 | -77.850 | 4.196.700 | |
| 2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -16.850 | 1.188.131 | -1,40 | 18,00 | -303.300 | 21.386.358 | |
| 2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -25.234 | 1.642.186 | -1,51 | 18,00 | -454.212 | 29.559.348 | |
| 2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -568.019 | 686.974 | -45,26 | 4,14 | -2.350.917 | 2.843.248 | |
| 2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -2.458.838 | 4.172.298 | -37,08 | 4,14 | -10.176.639 | 17.268.307 | |
| 2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -2.821.663 | 5.663.912 | -33,25 | 4,14 | -11.678.299 | 23.441.799 | |
| 2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 43.422 | 426.206 | 11,34 | 24,75 | 1.074.694 | 10.548.598 | |
| 2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 343.444 | 2.588.511 | 15,30 | 24,75 | 8.500.239 | 64.065.647 | |
| 2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 457.814 | 3.513.335 | 14,98 | 24,75 | 11.330.896 | 86.955.041 | |
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -1.757 | 6.758 | -20,63 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -9.169 | 39.693 | -18,77 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -11.776 | 52.145 | -18,42 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -35 | 0 | -100,00 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -203 | 0 | -100,00 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -273 | 0 | -100,00 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 97.615 | 113.152 | 628,27 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 1.944 | 15.537 | 14,30 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 509.410 | 598.624 | 571,00 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 11.278 | 89.214 | 14,47 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 654.215 | 771.780 | 556,47 | ||||
| 2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 15.166 | 117.565 | 14,81 | ||||
| 2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
2.945.743 | ||||||||
| 2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
2.164.406 | ||||||||
| 2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
358.450 | ||||||||
| 2020-12-22 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 45.032 | 2.245.067 | 2,05 | 16,05 | 722.764 | 36.033.325 | |
| 2020-12-22 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 114.968 | 3.055.521 | 3,91 | 16,05 | 1.845.236 | 49.041.112 | |
| 2020-12-15 |
|
4 | XOMA |
XOMA Corp
8.625% Series A Cumulative Perpetual Preferred Stock |
P - Purchase | 200.000 | 200.000 | 25,00 | 5.000.000 | 5.000.000 | ||
| 2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -25.486 | 463.244 | -5,21 | 18,00 | -458.748 | 8.338.392 | |
| 2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -166.194 | 2.760.185 | -5,68 | 18,00 | -2.991.492 | 49.683.330 | |
| 2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -239.274 | 3.811.271 | -5,91 | 18,00 | -4.306.932 | 68.602.878 | |
| 2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
4.050.545 | ||||||||
| 2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
2.926.379 | ||||||||
| 2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
488.730 | ||||||||
| 2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -93 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -551 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -740 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -73.399 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -522.403 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -760.155 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -101.784 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -673.281 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -889.186 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -185.908 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -881.156 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -1.129.404 | 0 | -100,00 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 74.991 | 436.082 | 20,77 | 19,00 | 1.424.829 | 8.285.558 | |
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 73.399 | 361.091 | 25,51 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 101.784 | 287.692 | 54,75 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 185.908 | 185.908 | |||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 446.425 | 2.523.265 | 21,50 | 19,00 | 8.482.075 | 47.942.035 | |
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 522.403 | 2.076.840 | 33,61 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 673.281 | 1.554.437 | 76,41 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 881.156 | 881.156 | |||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 613.918 | 3.392.663 | 22,09 | 19,00 | 11.664.442 | 64.460.597 | |
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 760.155 | 2.778.745 | 37,66 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 889.186 | 2.018.590 | 78,73 | ||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 1.129.404 | 1.129.404 | |||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21.520 | 21.520 | |||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21.520 | 21.520 | |||||
| 2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21.520 | 21.520 | |||||
| 2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
3.822.766 | ||||||||
| 2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
2.777.320 | ||||||||
| 2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
465.924 | ||||||||
| 2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -502.649 | 81.263 | -86,08 | 20,19 | -10.146.825 | 1.640.432 | |
| 2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -2.949.477 | 485.513 | -85,87 | 20,19 | -59.540.207 | 9.800.905 | |
| 2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -3.941.214 | 670.695 | -85,46 | 20,19 | -79.560.105 | 13.539.119 | |
| 2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 86.090 | 630.453 | 15,81 | 2,60 | 223.834 | 1.639.178 | |
| 2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 506.155 | 3.712.350 | 15,79 | 2,60 | 1.316.003 | 9.652.110 | |
| 2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 674.492 | 4.980.812 | 15,66 | 2,60 | 1.753.679 | 12.950.111 | |
| 2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.334 | 583.912 | 0,40 | 4,98 | 11.633 | 2.910.217 | |
| 2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 10.436 | 3.434.990 | 0,30 | 4,98 | 52.013 | 17.119.990 | |
| 2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 17.230 | 4.611.909 | 0,37 | 4,98 | 85.874 | 22.985.754 | |
| 2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15.355 | 581.578 | 2,71 | 4,88 | 74.997 | 2.840.543 | |
| 2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 143.403 | 3.424.554 | 4,37 | 4,88 | 700.409 | 16.726.207 | |
| 2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 257.804 | 4.594.679 | 5,94 | 4,88 | 1.259.166 | 22.441.331 | |
| 2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 15.472 | 544.363 | 2,93 | 2,75 | 42.548 | 1.496.998 | |
| 2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 250.755 | 3.206.195 | 8,48 | 2,75 | 689.576 | 8.817.036 | |
| 2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 666.385 | 4.306.320 | 18,31 | 2,75 | 1.832.559 | 11.842.380 | |
| 2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 25.107 | 566.223 | 4,64 | 5,04 | 126.414 | 2.850.933 | |
| 2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 162.352 | 3.281.151 | 5,21 | 5,04 | 817.442 | 16.520.595 | |
| 2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 157.782 | 4.336.875 | 3,78 | 5,04 | 794.432 | 21.836.166 | |
| 2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
102.400 | ||||||||
| 2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
77.936 | ||||||||
| 2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
13.595 | ||||||||
| 2020-09-24 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 32 | 541.116 | 0,01 | 3,80 | 122 | 2.055.537 | |
| 2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 7.201 | 1.750.704 | 0,41 | 18,20 | 131.057 | 31.862.463 | |
| 2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.888 | 2.040.124 | 0,49 | 18,20 | 179.960 | 37.129.849 | |
| 2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4.991 | 1.743.503 | 0,29 | 18,45 | 92.062 | 32.160.133 | |
| 2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6.960 | 2.030.236 | 0,34 | 18,45 | 128.382 | 37.449.124 | |
| 2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.069 | 1.738.512 | 0,58 | 18,39 | 185.120 | 31.962.717 | |
| 2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 12.259 | 2.023.276 | 0,61 | 18,39 | 225.383 | 37.198.132 | |
| 2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 10.258 | 382.784 | 2,75 | 11,75 | 120.532 | 4.497.712 | |
| 2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 58.745 | 2.200.035 | 2,74 | 11,75 | 690.254 | 25.850.411 | |
| 2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 77.751 | 2.940.553 | 2,72 | 11,75 | 913.574 | 34.551.498 | |
| 2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 12.816 | 372.526 | 3,56 | 11,10 | 142.235 | 4.134.368 | |
| 2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 76.374 | 2.141.290 | 3,70 | 11,10 | 847.614 | 23.764.465 | |
| 2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 100.461 | 2.862.802 | 3,64 | 11,10 | 1.114.936 | 31.771.949 | |
| 2020-09-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.830 | 1.728.443 | 0,22 | 18,77 | 71.891 | 32.443.912 | |
| 2020-09-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.907 | 2.011.017 | 0,19 | 18,77 | 73.337 | 37.747.996 | |
| 2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 14.339 | 359.710 | 4,15 | 11,17 | 160.167 | 4.017.961 | |
| 2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 82.740 | 2.064.916 | 4,17 | 11,17 | 924.206 | 23.065.112 | |
| 2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 104.827 | 2.762.341 | 3,94 | 11,17 | 1.170.918 | 30.855.349 | |
| 2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 7.672 | 1.724.613 | 0,45 | 18,87 | 144.741 | 32.536.721 | |
| 2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.900 | 2.007.110 | 0,50 | 18,87 | 186.774 | 37.866.338 | |
| 2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6.862 | 1.716.941 | 0,40 | 18,48 | 126.814 | 31.730.100 | |
| 2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.143 | 1.997.210 | 0,46 | 18,48 | 168.968 | 36.909.639 | |
| 2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 922 | 1.710.079 | 0,05 | 19,17 | 17.676 | 32.785.464 | |
| 2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.122 | 1.988.067 | 0,06 | 19,17 | 21.511 | 38.115.022 | |
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -180.686 | 0 | -100,00 | ||||
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1.000.955 | 0 | -100,00 | ||||
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1.336.390 | 0 | -100,00 | ||||
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 67.791 | 181.081 | 59,84 | 20,00 | 1.355.820 | 3.621.620 | |
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 113.290 | 113.290 | |||||
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 389.709 | 1.017.307 | 62,10 | 20,00 | 7.794.180 | 20.346.140 | |
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 627.598 | 627.598 | |||||
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 521.193 | 1.359.109 | 62,20 | 20,00 | 10.423.860 | 27.182.180 | |
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 837.916 | 837.916 | |||||
| 2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | -40.127 | 40.127 | -50,00 | ||||
| 2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 2.244 | 1.709.157 | 0,13 | 19,74 | 44.308 | 33.747.305 | |
| 2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.443 | 1.986.945 | 0,17 | 19,74 | 67.982 | 39.232.229 | |
| 2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 5.179 | 1.706.913 | 0,30 | 19,31 | 100.003 | 32.959.295 | |
| 2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6.504 | 1.983.502 | 0,33 | 19,31 | 125.588 | 38.300.035 | |
| 2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.607 | 1.701.734 | 0,09 | 19,32 | 31.050 | 32.880.224 | |
| 2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.198 | 1.976.998 | 0,47 | 19,32 | 177.720 | 38.198.765 | |
| 2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 158 | 3.547 | 4,66 | 35,79 | 5.655 | 126.947 | |
| 2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 905 | 20.390 | 4,64 | 35,79 | 32.390 | 729.758 | |
| 2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 1.205 | 27.265 | 4,62 | 35,79 | 43.127 | 975.814 | |
| 2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.772 | 1.967.800 | 0,09 | 19,12 | 33.881 | 37.624.336 | |
| 2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.496 | 1.966.028 | 0,18 | 19,70 | 68.877 | 38.733.897 | |
| 2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 895 | 1.962.532 | 0,05 | 19,27 | 17.246 | 37.816.814 | |
| 2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 21.922 | 1.961.637 | 1,13 | 18,69 | 409.810 | 36.670.842 | |
| 2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1.050 | 1.939.715 | 0,05 | 17,80 | 18.693 | 34.533.134 | |
| 2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4.050 | 1.938.665 | 0,21 | 17,34 | 70.233 | 33.619.359 | |
| 2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 81 | 237.475 | 0,03 | 13,32 | 1.079 | 3.162.312 | |
| 2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 929 | 1.204.981 | 0,08 | 13,32 | 12.371 | 16.046.009 | |
| 2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 1.521 | 1.667.420 | 0,09 | 13,32 | 20.254 | 22.204.032 | |
| 2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 1.354 | 237.394 | 0,57 | 13,93 | 18.868 | 3.308.014 | |
| 2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 7.854 | 1.204.052 | 0,66 | 13,93 | 109.443 | 16.778.103 | |
| 2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10.524 | 1.665.899 | 0,64 | 13,93 | 146.649 | 23.213.803 | |
| 2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 6.769 | 236.040 | 2,95 | 14,39 | 97.403 | 3.396.498 | |
| 2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 39.052 | 1.196.198 | 3,37 | 14,39 | 561.939 | 17.212.691 | |
| 2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 52.443 | 1.655.375 | 3,27 | 14,39 | 754.629 | 23.820.019 | |
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.592.281 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4.146.495 | ||||||||
| 2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3.218.620 | ||||||||
| 2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 6.967 | 345.371 | 2,06 | 15,20 | 105.898 | 5.249.639 | |
| 2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 33.321 | 1.982.176 | 1,71 | 15,20 | 506.479 | 30.129.075 | |
| 2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 46.966 | 2.657.514 | 1,80 | 15,20 | 713.883 | 40.394.213 | |
| 2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 94.101 | 338.404 | 38,52 | 14,00 | 1.317.414 | 4.737.656 | |
| 2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 561.966 | 1.948.855 | 40,52 | 14,00 | 7.867.524 | 27.283.970 | |
| 2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 806.443 | 2.610.548 | 44,70 | 14,00 | 11.290.202 | 36.547.672 | |
| 2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -192.250 | 480.432 | -28,58 | 6,00 | -1.153.500 | 2.882.592 | |
| 2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -1.064.332 | 2.766.561 | -27,78 | 6,00 | -6.385.992 | 16.599.366 | |
| 2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -1.027.016 | 3.712.340 | -21,67 | 6,00 | -6.162.096 | 22.274.040 | |
| 2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4.476 | 541.084 | 0,83 | 4,10 | 18.352 | 2.218.444 | |
| 2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 39.810 | 3.118.799 | 1,29 | 4,10 | 163.221 | 12.787.076 | |
| 2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 249.301 | 4.179.093 | 6,34 | 4,10 | 1.022.134 | 17.134.281 | |
| 2020-04-17 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
C - Conversion | -597 | 0 | -100,00 | ||||
| 2020-04-17 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
C - Conversion | -656 | 0 | -100,00 | ||||
| 2020-04-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 596.813 | 1.700.127 | 54,09 | 13,00 | 7.758.569 | 22.101.651 | |
| 2020-04-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 655.959 | 1.934.615 | 51,30 | 13,00 | 8.527.467 | 25.149.995 | |
| 2020-03-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8.264 | 1.278.656 | 0,65 | 17,20 | 142.129 | 21.991.093 | |
| 2020-03-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4.439 | 1.270.392 | 0,35 | 14,52 | 64.475 | 18.451.936 | |
| 2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8.113 | 1.265.953 | 0,64 | 15,73 | 127.648 | 19.918.125 | |
| 2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.164 | 1.257.840 | 0,81 | 15,73 | 159.916 | 19.790.351 | |
| 2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 100.000 | 1.247.676 | 8,71 | 18,34 | 1.834.090 | 22.883.501 | |
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 12 | 12 | |||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 87 | 191 | 83,65 | ||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 841 | 1.250 | 205,62 | ||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 981 | 1.594 | 160,03 | ||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 104 | 104 | |||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -104 | 0 | -100,00 | ||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 409 | 409 | |||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -409 | 0 | -100,00 | ||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 613 | 613 | |||||
| 2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -613 | 0 | -100,00 | ||||
| 2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -74.893 | 424.419 | -15,00 | 15,79 | -1.182.321 | 6.700.218 | |
| 2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -510.793 | 2.350.829 | -17,85 | 15,79 | -8.063.787 | 37.112.067 | |
| 2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -486.344 | 3.131.432 | -13,44 | 15,79 | -7.677.815 | 49.435.291 | |
| 2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 19.727 | 244.303 | 8,78 | 16,15 | 318.591 | 3.945.493 | |
| 2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 112.561 | 1.386.889 | 8,83 | 16,15 | 1.817.860 | 22.398.257 | |
| 2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 146.442 | 1.804.105 | 8,83 | 16,15 | 2.365.038 | 29.136.296 | |
| 2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 5.406 | 224.576 | 2,47 | 14,98 | 80.973 | 3.363.789 | |
| 2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 25.108 | 1.274.328 | 2,01 | 14,98 | 376.078 | 19.087.395 | |
| 2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 53.448 | 1.657.663 | 3,33 | 14,98 | 800.566 | 24.829.139 | |
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.676.820 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4.321.825 | ||||||||
| 2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3.291.775 | ||||||||
| 2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 32.606 | 536.608 | 6,47 | 4,05 | 132.054 | 2.173.262 | |
| 2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 201.096 | 3.078.989 | 6,99 | 4,05 | 814.439 | 12.469.905 | |
| 2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 281.318 | 3.929.792 | 7,71 | 4,05 | 1.139.338 | 15.915.658 | |
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 165.961 | 1.103.314 | 17,71 | 22,00 | 3.651.142 | 24.272.908 | |
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 207.234 | 1.147.676 | 22,04 | 22,00 | 4.559.148 | 25.248.872 | |
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -35.888 | 0 | -100,00 | ||||
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -190.899 | 0 | -100,00 | ||||
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -245.481 | 0 | -100,00 | ||||
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 35.888 | 159.537 | 29,02 | 22,00 | 789.536 | 3.509.814 | |
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 190.899 | 937.353 | 25,57 | 22,00 | 4.199.778 | 20.621.766 | |
| 2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 245.481 | 940.442 | 35,32 | 22,00 | 5.400.582 | 20.689.724 | |
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10.080.782 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9.353.356 | ||||||||
| 2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7.112.414 | ||||||||
| 2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 8.506 | 499.312 | 1,73 | 9,52 | 80.935 | 4.750.954 | |
| 2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 49.804 | 2.861.622 | 1,77 | 9,52 | 473.885 | 27.228.333 | |
| 2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 60.103 | 3.617.776 | 1,69 | 9,52 | 571.880 | 34.423.139 | |
| 2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 15.030 | 490.806 | 3,16 | 9,40 | 141.282 | 4.613.576 | |
| 2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 95.100 | 2.811.818 | 3,50 | 9,40 | 893.940 | 26.431.089 | |
| 2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 113.529 | 3.557.673 | 3,30 | 9,40 | 1.067.173 | 33.442.126 | |
| 2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.397 | 504.002 | 0,48 | 4,02 | 9.630 | 2.024.828 | |
| 2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 18.729 | 2.877.893 | 0,66 | 4,02 | 75.244 | 11.561.935 | |
| 2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 113.874 | 3.648.474 | 3,22 | 4,02 | 457.489 | 14.657.744 | |
| 2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81.857 | 501.605 | 19,50 | 3,40 | 278.322 | 1.705.507 | |
| 2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 462.056 | 2.859.164 | 19,28 | 3,40 | 1.571.037 | 9.721.444 | |
| 2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 576.097 | 3.534.600 | 19,47 | 3,40 | 1.958.787 | 12.017.993 | |
| 2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 14.151 | 672.682 | 2,15 | 3,91 | 55.353 | 2.631.263 | |
| 2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 79.285 | 3.830.893 | 2,11 | 3,91 | 310.131 | 14.984.921 | |
| 2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 98.518 | 4.739.356 | 2,12 | 3,91 | 385.363 | 18.538.465 | |
| 2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 11.105 | 658.531 | 1,72 | 3,37 | 37.424 | 2.219.249 | |
| 2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 45.888 | 3.751.608 | 1,24 | 3,37 | 154.643 | 12.642.919 | |
| 2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 71.495 | 4.640.838 | 1,56 | 3,37 | 240.938 | 15.639.624 | |
| 2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 70.921 | 419.748 | 20,33 | 4,00 | 283.684 | 1.678.992 | |
| 2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 400.470 | 2.397.108 | 20,06 | 4,00 | 1.601.880 | 9.588.432 | |
| 2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 496.721 | 2.958.503 | 20,18 | 4,00 | 1.986.884 | 11.834.012 | |
| 2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 57.868 | 647.426 | 9,82 | 2,70 | 156.244 | 1.748.050 | |
| 2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 331.048 | 3.705.720 | 9,81 | 2,70 | 893.830 | 10.005.444 | |
| 2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 408.592 | 4.569.343 | 9,82 | 2,70 | 1.103.198 | 12.337.226 | |
| 2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 116.552 | 589.558 | 24,64 | 2,60 | 303.035 | 1.532.851 | |
| 2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 610.052 | 3.374.672 | 22,07 | 2,60 | 1.586.135 | 8.774.147 | |
| 2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 872.373 | 4.160.751 | 26,53 | 2,60 | 2.268.170 | 10.817.953 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 504 | 348.827 | 0,14 | 3,85 | 1.940 | 1.342.844 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.913 | 1.996.638 | 0,15 | 3,85 | 11.214 | 7.686.258 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3.416 | 2.461.782 | 0,14 | 3,85 | 13.150 | 9.476.876 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.456 | 348.323 | 0,42 | 3,89 | 5.667 | 1.355.708 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 8.236 | 1.993.725 | 0,41 | 3,89 | 32.055 | 7.759.777 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 10.389 | 2.458.366 | 0,42 | 3,89 | 40.435 | 9.568.206 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 240 | 346.867 | 0,07 | 3,90 | 935 | 1.351.706 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.133 | 1.985.489 | 0,06 | 3,90 | 4.415 | 7.737.252 | |
| 2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.027 | 2.447.977 | 0,04 | 3,90 | 4.002 | 9.539.522 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.155 | 346.627 | 0,63 | 3,75 | 8.075 | 1.298.915 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 12.899 | 1.984.356 | 0,65 | 3,75 | 48.336 | 7.435.977 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15.728 | 2.446.950 | 0,65 | 3,75 | 58.938 | 9.169.456 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.629 | 344.472 | 0,48 | 3,74 | 6.100 | 1.289.944 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 57.723 | 1.971.457 | 3,02 | 3,74 | 216.155 | 7.382.515 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 76.036 | 2.431.222 | 3,23 | 3,74 | 284.732 | 9.104.197 | |
| 2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3.200 | 2.355.186 | 0,14 | 3,75 | 11.986 | 8.821.349 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4.689 | 342.843 | 1,39 | 3,68 | 17.270 | 1.262.691 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 24.716 | 1.913.734 | 1,31 | 3,68 | 91.029 | 7.048.282 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 31.007 | 2.351.986 | 1,34 | 3,68 | 114.199 | 8.662.364 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 24.425 | 338.154 | 7,79 | 3,75 | 91.594 | 1.268.078 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 14.242 | 313.729 | 4,76 | 3,75 | 53.382 | 1.175.919 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 138.609 | 1.889.018 | 7,92 | 3,75 | 519.784 | 7.083.818 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 80.821 | 1.750.409 | 4,84 | 3,75 | 302.933 | 6.560.883 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 168.640 | 2.320.979 | 7,84 | 3,75 | 632.400 | 8.703.671 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 98.333 | 2.152.339 | 4,79 | 3,75 | 368.572 | 8.067.397 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 991 | 299.487 | 0,33 | 3,74 | 3.704 | 1.119.333 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 7.314 | 1.669.588 | 0,44 | 3,74 | 27.336 | 6.240.085 | |
| 2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 7.695 | 2.054.006 | 0,38 | 3,74 | 28.760 | 7.676.847 | |
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6.053.392 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5.669.355 | ||||||||
| 2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4.305.577 | ||||||||
| 2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -1.128 | 314.139 | -0,36 | 4,50 | -5.075 | 1.413.437 | |
| 2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -25.720 | 2.233.074 | -1,14 | 4,50 | -115.725 | 10.047.493 | |
| 2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -23.152 | 2.385.055 | -0,96 | 4,50 | -104.170 | 10.731.316 | |
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.390.475 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.241.062 | ||||||||
| 2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.297.535 | ||||||||
| 2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 124.956 | 528.891 | 30,93 | 3,18 | 397.610 | 1.682.931 | |
| 2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 689.834 | 2.955.440 | 30,45 | 3,18 | 2.195.052 | 9.404.210 | |
| 2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 853.956 | 3.639.935 | 30,65 | 3,18 | 2.717.288 | 11.582.273 | |
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8.241.499 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7.721.126 | ||||||||
| 2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5.859.455 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.814.382 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9.290.624 | ||||||||
| 2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6.999.010 | ||||||||
| 2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -29.450 | 169.589 | -14,80 | 10,70 | -315.230 | 1.815.264 | |
| 2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -158.583 | 952.859 | -14,27 | 10,70 | -1.697.457 | 10.199.307 | |
| 2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -198.256 | 1.178.904 | -14,40 | 10,70 | -2.122.112 | 12.618.871 | |
| 2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 13.816 | 746.454 | 1,89 | 14,74 | 203.664 | 11.003.628 | |
| 2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3.797 | 732.638 | 0,52 | 14,36 | 54.526 | 10.520.975 | |
| 2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.300 | 728.841 | 1,43 | 14,57 | 150.037 | 10.616.808 | |
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4.064.801 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3.799.083 | ||||||||
| 2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2.886.680 | ||||||||
| 2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 284 | 284 | |||||
| 2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 2.143 | 2.143 | |||||
| 2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 2.573 | 2.573 | |||||
| 2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -284.000 | 141.346 | -66,77 | ||||
| 2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -2.143.000 | 772.324 | -73,51 | ||||
| 2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -2.573.000 | 978.200 | -72,45 | ||||
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 372 | 597 | 165,47 | 13.000,00 | 4.836.000 | 7.758.569 | |
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 311 | 656 | 89,96 | 13.000,00 | 4.038.398 | 8.527.467 | |
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 25.000 | 718.541 | 3,60 | 14,19 | 354.792 | 10.197.318 | |
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 225 | 225 | 13.000,00 | 2.922.569 | 2.922.569 | ||
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Subscription Rights |
X - Other | -225 | 0 | -100,00 | ||||
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 345 | 345 | 13.000,00 | 4.489.069 | 4.489.069 | ||
| 2018-12-19 |
|
4 | XOMA |
XOMA Corp
Subscription Rights |
X - Other | -345 | 0 | -100,00 | ||||
| 2018-12-17 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 120.539 | 6.631.136 | 1,85 | 1,20 | 144.587 | 7.954.048 | |
| 2018-12-17 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 54.461 | 8.485.575 | 0,65 | 1,20 | 65.326 | 10.178.447 | |
| 2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 24.253 | 693.541 | 3,62 | 14,41 | 349.525 | 9.995.035 | |
| 2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 2.810 | 669.288 | 0,42 | 14,75 | 41.448 | 9.871.998 | |
| 2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.400 | 666.478 | 1,43 | 14,50 | 136.270 | 9.661.798 | |
| 2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 18.081 | 657.078 | 2,83 | 14,54 | 262.972 | 9.556.608 | |
| 2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 32.015 | 638.997 | 5,27 | 14,77 | 472.778 | 9.436.324 | |
| 2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.927 | 606.982 | 1,83 | 14,80 | 161.698 | 8.982.120 | |
| 2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4.171 | 596.055 | 0,70 | 14,99 | 62.515 | 8.933.672 | |
| 2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 806 | 591.884 | 0,14 | 14,90 | 12.009 | 8.819.072 | |
| 2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4.823 | 591.078 | 0,82 | 14,85 | 71.615 | 8.776.681 | |
| 2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -89.948 | 370.391 | -19,54 | 1,83 | -164.929 | 679.149 | |
| 2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -382.017 | 1.942.764 | -16,43 | 1,83 | -700.466 | 3.562.252 | |
| 2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -430.035 | 2.502.758 | -14,66 | 1,83 | -788.512 | 4.589.057 | |
| 2018-11-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 100.000 | 6.510.597 | 1,56 | 1,30 | 130.000 | 8.463.776 | |
| 2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.016 | 586.255 | 1,74 | 14,93 | 149.543 | 8.753.022 | |
| 2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8.288 | 576.239 | 1,46 | 15,11 | 125.262 | 8.709.046 | |
| 2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 11.396 | 567.951 | 2,05 | 15,24 | 173.680 | 8.655.800 | |
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10.443.070 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9.807.194 | ||||||||
| 2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.317.216 | ||||||||
| 2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 25.000 | 556.555 | 4,70 | 15,00 | 374.892 | 8.345.932 | |
| 2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 37.482 | 531.555 | 7,59 | 13,68 | 512.701 | 7.270.928 | |
| 2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9.771 | 494.073 | 2,02 | 13,93 | 136.064 | 6.880.115 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 581 | 1.254.993 | 0,05 | 1,35 | 784 | 1.694.241 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4.119 | 8.431.114 | 0,05 | 1,35 | 5.561 | 11.382.004 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 5.573 | 1.254.412 | 0,45 | 1,35 | 7.524 | 1.693.456 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 38.001 | 6.410.597 | 0,60 | 1,35 | 51.301 | 8.654.306 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 50.044 | 8.426.995 | 0,60 | 1,35 | 67.559 | 11.376.443 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81.648 | 1.248.839 | 7,00 | 1,37 | 111.841 | 1.710.660 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 556.709 | 6.372.596 | 9,57 | 1,37 | 762.580 | 8.729.182 | |
| 2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 733.151 | 8.376.951 | 9,59 | 1,37 | 1.004.270 | 11.474.747 | |
| 2018-11-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10.849 | 484.302 | 2,29 | 13,82 | 149.986 | 6.695.427 | |
| 2018-11-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 21.141 | 473.453 | 4,67 | 13,31 | 281.361 | 6.301.091 | |
| 2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 39.074 | 5.815.887 | 0,68 | 1,35 | 52.750 | 7.851.447 | |
| 2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 52.400 | 7.643.800 | 0,69 | 1,35 | 70.740 | 10.319.130 | |
| 2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 92.960 | 5.776.813 | 1,64 | 1,34 | 124.566 | 7.740.929 | |
| 2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 117.290 | 7.591.400 | 1,57 | 1,34 | 157.169 | 10.172.476 | |
| 2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 562.754 | 5.683.853 | 10,99 | 1,35 | 759.718 | 7.673.202 | |
| 2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 41.454 | 7.474.110 | 0,56 | 1,35 | 55.963 | 10.090.048 | |
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.650.706 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8.042.694 | ||||||||
| 2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6.178.252 | ||||||||
| 2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 36.825 | 1.167.191 | 3,26 | 1,65 | 60.761 | 1.925.865 | |
| 2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 158.151 | 5.121.099 | 3,19 | 1,65 | 260.949 | 8.449.813 | |
| 2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 230.555 | 7.432.656 | 3,20 | 1,65 | 380.416 | 12.263.882 | |
| 2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 179.893 | 1.130.366 | 18,93 | 1,65 | 296.823 | 1.865.104 | |
| 2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.419.907 | 4.962.948 | 40,08 | 1,65 | 2.342.847 | 8.188.864 | |
| 2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.916.760 | 7.202.101 | 36,27 | 1,65 | 3.162.654 | 11.883.467 | |
| 2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 188.746 | 188.746 | |||||
| 2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 705.863 | 705.863 | |||||
| 2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 1.105.391 | 1.105.391 | |||||
| 2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -188.746 | 85.038 | -68,94 | ||||
| 2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -705.863 | 318.021 | -68,94 | ||||
| 2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -1.105.391 | 498.025 | -68,94 | ||||
| 2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -175.813 | 771.305 | -18,56 | 5,00 | -879.083 | 3.856.602 | |
| 2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -312.266 | 3.186.044 | -8,93 | 5,00 | -1.561.361 | 15.930.539 | |
| 2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -547.860 | 4.682.669 | -10,47 | 5,00 | -2.739.355 | 23.413.813 | |
| 2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -217.256 | 947.118 | -18,66 | 3,10 | -673.494 | 2.936.066 | |
| 2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -808.449 | 3.498.310 | -18,77 | 3,10 | -2.506.192 | 10.844.761 | |
| 2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -1.204.668 | 5.230.529 | -18,72 | 3,10 | -3.734.471 | 16.214.640 | |
| 2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 97.453 | 950.473 | 11,42 | 2,00 | 194.906 | 1.900.946 | |
| 2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 365.682 | 3.543.041 | 11,51 | 2,00 | 731.364 | 7.086.082 | |
| 2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 546.865 | 5.285.341 | 11,54 | 2,00 | 1.093.730 | 10.570.682 | |
| 2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 62.437 | 853.020 | 7,90 | 1,90 | 118.630 | 1.620.738 | |
| 2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 208.872 | 3.177.359 | 7,04 | 1,90 | 396.857 | 6.036.982 | |
| 2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 228.691 | 4.738.476 | 5,07 | 1,90 | 434.513 | 9.003.104 | |
| 2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -214.336 | 1.164.374 | -15,55 | 2,90 | -621.574 | 3.376.685 | |
| 2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -817.611 | 4.306.759 | -15,96 | 2,90 | -2.371.072 | 12.489.601 | |
| 2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -1.269.634 | 6.435.197 | -16,48 | 2,90 | -3.681.939 | 18.662.071 | |
| 2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 238.000 | 238.000 | |||||
| 2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 861.000 | 861.000 | |||||
| 2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 1.338.000 | 1.338.000 | |||||
| 2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -238.000 | 59.464 | -80,01 | ||||
| 2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -861.000 | 216.694 | -79,89 | ||||
| 2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -1.338.000 | 336.468 | -79,91 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 2.280 | 2.280 | |||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 1.024 | 1.024 | |||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 3.640 | 3.640 | |||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 5.631 | 5.631 | |||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -49 | 0 | -100,00 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -48 | 0 | -100,00 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -197 | 0 | -100,00 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -281 | 0 | -100,00 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 699.225 | 1.295.582 | 117,25 | 3,00 | 2.097.675 | 3.886.746 | |
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 483.708 | 483.708 | 3,00 | 1.451.124 | 1.451.124 | ||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 2.109.280 | 2.109.280 | 3,00 | 6.327.840 | 6.327.840 | ||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 3.041.120 | 3.041.120 | 3,00 | 9.123.360 | 9.123.360 | ||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -1.487.294 | 596.357 | -71,38 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -651.074 | 0 | -100,00 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -2.295.083 | 0 | -100,00 | ||||
| 2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -3.566.549 | 0 | -100,00 | ||||
| 2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -169.292 | 122.496 | -58,02 | 26,65 | -4.511.632 | 3.264.518 | |
| 2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -445.615 | 632.642 | -41,33 | 26,65 | -11.875.640 | 16.859.909 | |
| 2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -667.949 | 951.300 | -41,25 | 26,65 | -17.800.841 | 25.352.145 | |
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4.504.500 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.924.968 | ||||||||
| 2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3.174.868 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17.248.837 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15.027.176 | ||||||||
| 2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12.158.047 | ||||||||
| 2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 34.632 | 291.788 | 13,47 | 15,84 | 548.484 | 4.621.192 | |
| 2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 135.206 | 1.078.257 | 14,34 | 15,84 | 2.141.325 | 17.076.895 | |
| 2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 162.078 | 1.619.249 | 11,12 | 15,84 | 2.566.910 | 25.644.856 | |
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21.912.742 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19.332.281 | ||||||||
| 2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15.586.621 | ||||||||
| 2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 63.042 | 790.583 | 8,67 | 1,28 | 80.946 | 1.015.109 | |
| 2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 235.326 | 2.968.487 | 8,61 | 1,28 | 302.159 | 3.811.537 | |
| 2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 355.081 | 4.509.785 | 8,55 | 1,28 | 455.924 | 5.790.564 | |
| 2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 28.918 | 727.541 | 4,14 | 1,24 | 35.714 | 898.513 | |
| 2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 394.078 | 2.733.161 | 16,85 | 1,24 | 486.686 | 3.375.454 | |
| 2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 523.601 | 4.154.704 | 14,42 | 1,24 | 646.647 | 5.131.059 | |
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4.114.549 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3.600.429 | ||||||||
| 2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2.914.534 | ||||||||
| 2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 7.429 | 1.077.694 | 0,69 | 2,41 | 17.920 | 2.599.613 | |
| 2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 11.429 | 1.674.468 | 0,69 | 2,41 | 27.569 | 4.039.152 | |
| 2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 13.337 | 1.070.265 | 1,26 | 2,70 | 36.058 | 2.893.568 | |
| 2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 28.007 | 1.663.039 | 1,71 | 2,70 | 75.720 | 4.496.192 | |
| 2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 8.496 | 297.464 | 2,94 | 3,04 | 25.795 | 903.130 | |
| 2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 30.170 | 1.056.928 | 2,94 | 3,04 | 91.599 | 3.208.939 | |
| 2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 46.795 | 1.635.032 | 2,95 | 3,04 | 142.074 | 4.964.121 | |
| 2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 8.496 | 297.464 | 2,94 | 4,00 | 33.984 | 1.189.856 | |
| 2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 30.170 | 1.056.928 | 2,94 | 4,00 | 120.680 | 4.227.712 | |
| 2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 46.795 | 1.635.032 | 2,95 | 4,00 | 187.180 | 6.540.128 | |
| 2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 854 | 288.968 | 0,30 | 4,00 | 3.416 | 1.155.872 | |
| 2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 2.884 | 1.026.758 | 0,28 | 4,00 | 11.536 | 4.107.032 | |
| 2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 4.525 | 1.588.237 | 0,29 | 4,00 | 18.100 | 6.352.948 | |
| 2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1.362 | 288.114 | 0,47 | 4,00 | 5.448 | 1.152.456 | |
| 2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 4.406 | 1.023.874 | 0,43 | 4,00 | 17.624 | 4.095.496 | |
| 2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6.380 | 1.583.712 | 0,40 | 4,00 | 25.520 | 6.334.848 | |
| 2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.715 | 201.811 | 0,86 | 2,25 | 3.859 | 454.075 | |
| 2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.359 | 717.089 | 0,89 | 2,25 | 14.308 | 1.613.450 | |
| 2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 9.732 | 1.109.258 | 0,89 | 2,25 | 21.897 | 2.495.830 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 357 | 286.752 | 0,12 | 3,85 | 1.374 | 1.103.995 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1.271 | 1.019.468 | 0,12 | 3,85 | 4.893 | 3.924.952 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1.967 | 1.577.332 | 0,12 | 3,85 | 7.573 | 6.072.728 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1.064 | 286.395 | 0,37 | 3,85 | 4.096 | 1.102.621 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 3.873 | 1.018.197 | 0,38 | 3,85 | 14.911 | 3.920.058 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6.097 | 1.575.365 | 0,39 | 3,85 | 23.473 | 6.065.155 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1.160 | 285.331 | 0,41 | 3,84 | 4.451 | 1.094.815 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 3.845 | 1.014.324 | 0,38 | 3,84 | 14.753 | 3.891.961 | |
| 2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6.774 | 1.569.268 | 0,43 | 3,84 | 25.992 | 6.021.281 | |
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -536 | 49 | -91,62 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -513 | 48 | -91,44 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -2.115 | 197 | -91,48 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -3.011 | 281 | -91,46 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 585 | 585 | |||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 561 | 561 | |||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 2.312 | 2.312 | |||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 3.292 | 3.292 | |||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 357.333 | 2.083.651 | 20,70 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 342.000 | 651.074 | 110,65 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 1.410.000 | 2.295.083 | 159,31 | ||||
| 2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 2.007.333 | 3.566.549 | 128,74 | ||||
| 2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 20.594 | 284.171 | 7,81 | 3,85 | 79.312 | 1.094.399 | |
| 2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 73.749 | 1.010.479 | 7,87 | 3,85 | 284.022 | 3.891.557 | |
| 2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 113.446 | 1.562.494 | 7,83 | 3,85 | 436.903 | 6.017.477 | |
| 2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 913 | 263.577 | 0,35 | 3,75 | 3.424 | 988.414 | |
| 2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 53.260 | 936.730 | 6,03 | 3,75 | 199.725 | 3.512.738 | |
| 2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 96.736 | 1.449.048 | 7,15 | 3,75 | 362.760 | 5.433.930 | |
| 2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3.673 | 200.096 | 1,87 | 2,28 | 8.379 | 456.479 | |
| 2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 13.046 | 710.730 | 1,87 | 2,28 | 29.762 | 1.621.388 | |
| 2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 20.181 | 1.099.526 | 1,87 | 2,28 | 46.039 | 2.508.349 | |
| 2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3.920 | 196.423 | 2,04 | 2,29 | 8.979 | 449.927 | |
| 2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 12.624 | 697.684 | 1,84 | 2,29 | 28.917 | 1.598.115 | |
| 2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 19.206 | 1.079.345 | 1,81 | 2,29 | 43.993 | 2.472.348 | |
| 2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2.727 | 192.503 | 1,44 | 2,25 | 6.128 | 432.554 | |
| 2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10.023 | 685.060 | 1,48 | 2,25 | 22.522 | 1.539.330 | |
| 2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 15.350 | 1.060.139 | 1,47 | 2,25 | 34.491 | 2.382.132 | |
| 2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.805 | 189.776 | 0,96 | 2,30 | 4.144 | 435.669 | |
| 2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.903 | 675.037 | 1,03 | 2,30 | 15.847 | 1.549.682 | |
| 2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10.192 | 1.044.789 | 0,99 | 2,30 | 23.398 | 2.398.522 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1.124 | 187.971 | 0,60 | 2,30 | 2.585 | 432.333 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 4.223 | 668.134 | 0,64 | 2,30 | 9.713 | 1.536.708 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.253 | 1.034.597 | 0,61 | 2,30 | 14.382 | 2.379.573 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2.909 | 186.847 | 1,58 | 2,30 | 6.690 | 429.711 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10.541 | 663.911 | 1,61 | 2,30 | 24.242 | 1.526.863 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 16.436 | 1.028.344 | 1,62 | 2,30 | 37.800 | 2.364.986 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 5.510 | 183.938 | 3,09 | 2,30 | 12.666 | 422.818 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.897 | 653.370 | 1,07 | 2,30 | 15.854 | 1.501.902 | |
| 2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 24.965 | 1.011.908 | 2,53 | 2,30 | 57.387 | 2.326.073 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 675 | 178.428 | 0,38 | 2,34 | 1.581 | 418.039 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2.565 | 646.473 | 0,40 | 2,34 | 6.010 | 1.514.622 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3.794 | 986.943 | 0,39 | 2,34 | 8.889 | 2.312.309 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6.217 | 177.753 | 3,62 | 2,35 | 14.583 | 416.955 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 22.092 | 643.908 | 3,55 | 2,35 | 51.821 | 1.510.415 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 33.691 | 983.149 | 3,55 | 2,35 | 79.029 | 2.306.173 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3.929 | 171.536 | 2,34 | 2,29 | 8.989 | 392.457 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 14.274 | 621.816 | 2,35 | 2,29 | 32.657 | 1.422.653 | |
| 2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 21.797 | 949.458 | 2,35 | 2,29 | 49.869 | 2.172.265 | |
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.630.471 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2.310.352 | ||||||||
| 2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1.870.417 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.665.288 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4.098.367 | ||||||||
| 2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3.319.001 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2.197.761 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.955.112 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.626.449 | ||||||||
| 2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1.734.678 | ||||||||
| 2017-01-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3.234 | 2.339.083 | 0,14 | 1,34 | 4.333 | 3.133.669 | |
| 2017-01-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.145 | 3.631.103 | 0,03 | 1,34 | 1.534 | 4.864.589 | |
| 2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1.205 | 2.335.849 | 0,05 | 1,34 | 1.614 | 3.129.103 | |
| 2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.348 | 3.629.958 | 0,06 | 1,34 | 3.145 | 4.862.692 | |
| 2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 77.076 | 698.623 | 12,40 | 1,34 | 102.943 | 933.081 | |
| 2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 260.046 | 2.334.644 | 12,53 | 1,34 | 347.317 | 3.118.151 | |
| 2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 401.726 | 3.627.610 | 12,45 | 1,34 | 536.545 | 4.845.036 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.244 | 621.547 | 0,36 | 1,35 | 3.040 | 842.134 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 8.111 | 2.074.598 | 0,39 | 1,35 | 10.990 | 2.810.873 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 11.646 | 3.225.884 | 0,36 | 1,35 | 15.779 | 4.370.750 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 21.021 | 619.303 | 3,51 | 1,36 | 28.555 | 841.261 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 69.041 | 2.066.487 | 3,46 | 1,36 | 93.785 | 2.807.116 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 108.202 | 3.214.238 | 3,48 | 1,36 | 146.982 | 4.366.221 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 47.812 | 598.282 | 8,69 | 1,28 | 61.199 | 765.801 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 150.451 | 1.997.446 | 8,15 | 1,28 | 192.577 | 2.556.731 | |
| 2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 236.393 | 3.106.036 | 8,24 | 1,28 | 302.583 | 3.975.726 | |
| 2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2.916 | 550.470 | 0,53 | 1,19 | 3.470 | 655.114 | |
| 2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 18.586 | 1.846.995 | 1,02 | 1,19 | 22.119 | 2.198.109 | |
| 2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 30.998 | 2.869.643 | 1,09 | 1,19 | 36.891 | 3.415.162 | |
| 2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15.161 | 547.554 | 2,85 | 1,18 | 17.958 | 648.578 | |
| 2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 52.457 | 1.828.409 | 2,95 | 1,18 | 62.135 | 2.165.750 | |
| 2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81.276 | 2.838.645 | 2,95 | 1,18 | 96.271 | 3.362.375 | |
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7.823.083 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6.841.666 | ||||||||
| 2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5.598.107 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.850.758 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3.381.916 | ||||||||
| 2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2.761.110 | ||||||||
| 2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 6.197 | 6.197 | 800,00 | 4.957.600 | 4.957.600 | ||
| 2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 1.029 | 1.029 | 800,00 | 823.200 | 823.200 | ||
| 2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 4.519 | 4.519 | 800,00 | 3.615.200 | 3.615.200 | ||
| 2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 5.505 | 5.505 | 800,00 | 4.404.000 | 4.404.000 | ||
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 58.613 | 17.263.200 | 0,34 | 1,22 | 71.338 | 21.011.041 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 32.571 | 3.090.744 | 1,07 | 1,22 | 39.642 | 3.761.745 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 90.049 | 8.850.836 | 1,03 | 1,22 | 109.599 | 10.772.352 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 186.314 | 15.592.160 | 1,21 | 1,22 | 226.763 | 18.977.218 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 8.091 | 17.204.587 | 0,05 | 1,22 | 9.848 | 20.939.703 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 29.655 | 3.058.173 | 0,98 | 1,22 | 36.093 | 3.722.102 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 87.747 | 8.760.787 | 1,01 | 1,22 | 106.797 | 10.662.754 | |
| 2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 508.287 | 15.405.846 | 3,41 | 1,22 | 618.636 | 18.750.455 | |
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23.547.788 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21.842.395 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19.541.857 | ||||||||
| 2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29.064.800 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58.693.172 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52.468.653 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46.824.131 | ||||||||
| 2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60.992.109 |
